My research chair was renewed for the next five years.

L’Université de Montréal obtient 16 chaires de recherche du Canada

This chair is part of a 308 million dollar Canadian government investment in science and research.

I'm really happy to have been accepted as as delegate to this year's Science Meets Parliament, to network and learn about how science policy is made in Canada. I have so little knowledge in this area that I expect it to be a big learning opportunity for me.

The Spring 2022 CIHR competition was very successful for our lab with two funded projects. 

Denis Talbot (Laval) and I received funding for the project "The test-negative design for the estimation of COVID-19 vaccine effectiveness: design evaluation and development of statistical methods in the evolving context."

​

Lay abstract: 
Fast research designs have been proposed for estimating how well different vaccines protect against disease, severe disease, hospitalization, and death from COVID-19. In fact, ongoing study is needed to evaluate different levels of vaccination (2 doses, boosters, different lags between doses, etc) in terms of how well they protect against illness, which may vary depending on the current circulation of virus variants. These fast designs typically involve identifying people who have been tested for COVID-19, often at a test-site or in a hospital. An established design is called the "test-negative design" which specifically involves identifying people who have symptoms associated with the disease in question and who then get tested. Scientists can estimate vaccine effectiveness by comparing people who test positive to people who test negative. If the negatives have higher rates of vaccination, this will indicate effectiveness of the vaccine. But, depending on how the design and statistical methods are applied, there may be bias in the estimation of effectiveness. Our research team has recently noted that, because of challenges of how test data are collected in our healthcare systems across Canada, the classical version of the test-negative design cannot always be applied. For example, some designs have used all test data, rather than only data from those who have certain symptoms. We are interested in evaluating how much bias can be caused by this difference in design, and identifying scenarios in which this can create misleading results. Secondly, we are interested in developing statistical methods that can address the limitations of the regression approach that is essentially the only one currently being used. We will identify limitations of current methods and propose new (or adapted) methods that can address these limitations. Our goal is to produce more reliable statistical methods so that we can improve our monitoring of the benefits of vaccination.

The second project is with Drs Yiorgos Alexandros Cavayas (UdeM), François Martin Carrier (UdeM), and Eddy Fan (UToronto), and is entitled "Large reductions in arterial CARbon dioxide and development of acute Brain Injury in invasively mechanically ventilated patients with acute respiratory failure (CARBI)".

We're thrilled with the results and greatly appreciate the support from CIHR to continue our work developing and applying causal inference methods!

I am so happy to share that I've received a new investigator research award from the Association of Faculties of Pharmacy of Canada (AFPC)! The award announcement can be found here.

I also deeply appreciate the nomination and support from the Faculty of Pharmacy at Université de Montréal. 

Thanks to the AFPC and my faculty for the recognition of my research accomplishments and the work of my exceptional graduate students in these first 6 years!